Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
The NP resin portfolio, indicated by its UL746G-certified prefix, equips manufacturers across industries to meet increasingly stringent regulatory and performance standards
The move strengthens GBL’s clinical-stage presence in the United States
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates
Subscribe To Our Newsletter & Stay Updated
